CRC Research Update — September 20, 2026
Today's colorectal cancer research highlights
mrd
A collection of 32 issues
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
A structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing
CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection,
CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights
Tracking ctDNA after surgery identifies high-risk patients despite negative MRD status
Skip to content
The CRC Digest
◇ RESEARCH
Tracking ctDNA after surgery identifies high-risk patients despite negative MRD status
A longitudinal study of 124 stage II-III patients found that analyzing circulating tumor DNA (ctDNA) trajectories after surgery can identify subgroups at high risk for recurrence or metastasis, even when initial minimal
CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
Skip to content
The CRC Digest
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery)
This content is informational
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative Surgery
A review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
Skip to content
The CRC Digest
ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery
An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer